Princeton Global Asset Management’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $6.67M | Sell |
26,493
-302
| -1% | -$65K | 0.96% | 28 |
|
|
2026
Q1 | $5.83M | Sell |
26,795
-499
| -2% | -$111K | 0.95% | 28 |
|
|
2025
Q4 | $6.24M | Sell |
27,294
-593
| -2% | -$135K | 1.01% | 24 |
|
|
2025
Q3 | $6.46M | Sell |
27,887
-1,104
| -4% | -$225K | 1.07% | 24 |
|
|
2025
Q2 | $5.38M | Buy |
28,991
+213
| +0.7% | +$39.6K | 0.98% | 29 |
|
|
2025
Q1 | $6.03M | Sell |
28,778
-1,154
| -4% | -$224K | 1.2% | 24 |
|
|
2024
Q4 | $5.32M | Buy |
29,932
+273
| +0.9% | +$50.2K | 0.99% | 27 |
|
|
2024
Q3 | $5.86M | Buy |
29,659
+63
| +0.2% | +$11.8K | 1.14% | 23 |
|
|
2024
Q2 | $5.08M | Buy |
29,596
+528
| +2% | +$87.5K | 1.12% | 23 |
|
|
2024
Q1 | $5.29M | Sell |
29,068
-222
| -0.8% | -$38.3K | 1.26% | 21 |
|
|
2023
Q4 | $4.54M | Sell |
29,290
-1,265
| -4% | -$184K | 1.14% | 21 |
|
|
2023
Q3 | $4.55M | Sell |
30,555
-1,038
| -3% | -$152K | 1.29% | 20 |
|
|
2023
Q2 | $4.26M | Sell |
31,593
-12,849
| -29% | -$1.88M | 1.24% | 20 |
|
|
2023
Q1 | $7.08M | Sell |
44,442
-243
| -0.5% | -$37.2K | 2.04% | 8 |
|
|
2022
Q4 | $7.22M | Buy |
44,685
+99
| +0.2% | +$15.2K | 2.34% | 6 |
|
|
2022
Q3 | $5.98M | Sell |
44,586
-630
| -1% | -$90.4K | 2.09% | 7 |
|
|
2022
Q2 | $6.92M | Sell |
45,216
-1,194
| -3% | -$182K | 2.24% | 6 |
|
|
2022
Q1 | $7.52M | Buy |
46,410
+1,273
| +3% | +$185K | 2.09% | 11 |
|
|
2021
Q4 | $6.11M | Buy |
45,137
+648
| +1% | +$76.5K | 1.71% | 12 |
|
|
2021
Q3 | $4.8M | Sell |
44,489
-1,387
| -3% | -$158K | 1.46% | 15 |
|
|
2021
Q2 | $5.17M | Buy |
45,876
+13,648
| +42% | +$1.54M | 1.57% | 13 |
|
|
2021
Q1 | $3.49M | Buy |
32,228
+1,412
| +5% | +$151K | 1.13% | 23 |
|
|
2020
Q4 | $3.3M | Buy |
30,816
+471
| +2% | +$45.3K | 1.16% | 21 |
|
|
2020
Q3 | $2.66M | Sell |
30,345
-3,336
| -10% | -$314K | 1.07% | 27 |
|
|
2020
Q2 | $3.31M | Buy |
33,681
+17,656
| +110% | +$1.55M | 1.03% | 22 |
|
|
2020
Q1 | $1.22M | Buy |
16,025
+3,013
| +23% | +$257K | 0.54% | 57 |
|
|
2019
Q4 | $1.15K | Buy |
13,012
+4,002
| +44% | +$332K | 0.47% | 62 |
|
|
2019
Q3 | $660K | Buy |
9,010
+1,079
| +14% | +$74K | 0.38% | 76 |
|
|
2019
Q2 | $577K | Buy |
7,931
+244
| +3% | +$19.2K | 0.35% | 80 |
|
|
2019
Q1 | $619K | Buy |
7,687
+446
| +6% | +$36.5K | 0.42% | 64 |
|
|
2018
Q4 | $668K | Buy |
+7,241
| New | +$637K | 0.59% | 48 |
|
Other funds holding ABBV
Princeton Global Asset Management's ABBV Position: Q2 2026 in Review
Princeton Global Asset Management reduced its AbbVie (ABBV) stake by 1.1% in Q2 2026, selling an estimated $65K and leaving 26,493 shares worth $6.67M. The position accounts for 0.96% of the portfolio, ranked #28.
Princeton Global Asset Management first reported a position in ABBV in Q4 2018 and has held it in 31 quarters since. The position peaked at $7.52M in Q1 2022. 4,193 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Princeton Global Asset Management held 26,493 shares of AbbVie worth $6.67M as of Q2 2026.
- Princeton Global Asset Management sold 302 AbbVie shares in Q2 2026, an estimated $65K.
- AbbVie made up 0.96% of Princeton Global Asset Management's portfolio in Q2 2026, its #28 holding.
- Princeton Global Asset Management first reported a position in AbbVie in Q4 2018 and has held it in 31 quarters since.
- Princeton Global Asset Management's AbbVie position peaked at $7.52M in Q1 2022.
- 4,193 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Princeton Global Asset Management's 13F filing for Q2 2026, filed 16 Jul 2026.